Fidia Farmaceutici S.p.a. Enters the Italian Pediatric Market Segment
Fidia Farmaceutici S.p.a. (“Fidia”) enters the Italian pediatric healthcare market with the acquisition of the HALYKOO Line developed by the Swiss-based company APR Applied Pharma Research s.a. (“APR”), specialized in the development of innovative and patent-protected products (prescription and OTC), that are marketed worldwide through licensing and distribution agreements.
The HALYKOO products will be available in Italy starting next fall: this is the first complete line of products offering, under only one unique brand, tailor-made therapeutic solutions, designed and developed for children’s health and wellbeing since newborns.
This partnership has enabled Fidia, a leading Italian healthcare company specialized in the R&D and marketing of innovative products based on hyaluronic acid, to officially enter the pediatric market segment. “We are pleased to complement our portfolio with high-quality, safe and effective products, with innovative and child-friendly formulations, that offer reassurance to parents, many of whom are already acquainted with Fidia’s brand, also in taking care of their little ones.” – said Giorgio Foresti, Fidia Farmaceutici’s CEO. “The HALYKOO brand will integrate Fidia’s Personal Care product portfolio, that currently offers a range of treatment options for skin and mucosal health.”
“The Italian consumer market and especially the pediatric healthcare market has been steadily declining over the last few years” commented Giorgio Foresti. “However, HalyKoo represents a great opportunity to successfully compete in a worthy market segment such as baby healthcare, where we expect to reach an adequate market share despite the high fragmentation of this crowded market, with several hundred players at pharmacy level”.
Over the last 20 years, APR has developed high-quality products certified according to the strictest international regulations. “We design and develop science-driven, value-added products we market successfully in over 50 countries, including Europe and the USA, through licensing and distribution agreements with leading pharmaceutical companies.” – said Paolo Galfetti, CEO and co-founder of APR. “We are very pleased about the partnership with Fidia Farmaceutici because they are the ideal partner to take this innovative line to fruition for all Italian mothers.
About Halykoo
Halykoo is a new global brand in the pediatric
self-care market, conceived and developed by APR starting from an unmet
demand driven insight, which aims to transform the moments of child
healthcaring in a time of relation (between mother and kid) peaceful,
simple and safe in order to get parents’ confidence and smiling babies.
Halykoo is the first and only OTC pediatric healthcare brand that matches formulations specifically focused on each of the unique ages and stages of children’s growth, since birth, with smart and innovative formulations and delivery systems intended to simplify their use for parents and reduce the hassle for babies.
Halykoo products are the perfect combination of responsible, Swiss,
high-quality research combined with an extensive understanding of child
and caregivers needs: as a result, each Halykoo product provides the
right formula – from accurate selection of the ingredients (inlcuding
natural BIO certified components), to careful dosing of the active
principles and full compliance with the strictest safety standards - and
the right delivery system for the right age.
For more info about
Halykoo, please visit: www.halykoo.com
About Fidia Farmaceutici S.p.a.
Fidia Farmaceutici S.p.a. is
a multinational, integrated pharma company headquartered in Abano Terme,
Italy and based on extensive R&D on hyaluronan and its proprietary
derivatives, with specialized technology platforms, that enable the
company to produce hyaluronic acids with different molecular weights and
characteristics, according to the indications designed for the finished
products. Fidia Farmaceutici S.p.a. products are marketed in over 100
countries worldwide, through fully owned subsidiaries and a
comprehensive network of partnerships and distributors. The Company
operates in diverse therapeutic areas, providing a wide array of
innovative treatment options - medicinal products, medical devices,
nutritional supplements and biomaterials - for application in Joint
Healthcare, Wound Care, Dermatology and Aesthetics. Fidia Farmaceutici
SpA is part of P&R Holding, a chemical group operating in the
manufacturing of Active Pharmaceutical Ingredients, Advanced
Intermediates, and High Potency Drugs dedicated to diseases with high
socio-economic relevance. For more info, please visit www.fidiapharma.com.
About APR Applied Pharma Research s.a.
APR is an independent
Swiss company, specialized in the development of science-driven,
patent-protected healthcare products. The Company identifies, develops
and licenses science- driven, value-added products designed to address
patient or consumer needs in selected therapeutic areas on a global
basis. Specifically, APR is currently focused on 2 (two) major areas:
(i) internally developed and financed (alone or with our co-development
partners) proprietary, value-added products to be licensed to healthcare
companies for their commercialization, and (ii) support to third-party
projects, by offering value-added, R&D services under contract and fee
for service arrangements. APR has a balanced pipeline of
revenue-generating branded products marketed in all major markets,
combined with a compelling pipeline of products at different development
stages. APR has entered into licensing and partnership agreements with
pharmaceutical companies in over 70 countries, with international sales
on a worldwide basis. For more info, please visit: www.apr.ch.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150702005220/en/
Contact information
Fidia farmaceutici S.p.A
Elena Fedeli, Head of Communication
efedeli@fidiapharma.it
Tel
(+39) 049 8232359
Eleonora Cossa, Value Relations – PR Agency
e.cossa@vrelations.it
Tel.
+39 02.20424933
or
APR Applied Pharma Research s.a.
Paolo
Galfetti; Chief Executive Officer
T: +41 91 6957020 or email to paolo.galfetti@apr.ch
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo